COMPASS THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
COMPASS THERAPEUTICS, INC. (CMPX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.86% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.84%, a 10.28% decline year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.28%, a 5.94% increase year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.04%, a 6.32% increase year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.80%, a 105.41% increase year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.26%, a 8.67% increase from fiscal 2024.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.92%, a 2.35% increase from fiscal 2023.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.83%, a 89.60% increase from fiscal 2022.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.02%, a 137.65% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 3.86% 10-Q · filed 2026-08-06 | |||||
| 2026-03-31 | 3.84% 10-Q · filed 2026-05-05 | |||||
| 2025-12-31 | 4.26% 10-K · filed 2026-03-05 | |||||
| 2025-09-30 | 4.30% 10-Q · filed 2025-11-05 | |||||
| 2025-06-30 | 4.28% 10-Q · filed 2026-08-06 | |||||
| 2025-03-31 | 4.28% 10-Q · filed 2026-05-05 | |||||
| 2024-12-31 | 3.92% 10-K · filed 2026-03-05 | |||||
| 2024-09-30 | 3.90% 10-Q · filed 2025-11-05 | |||||
| 2024-06-30 | 4.04% 10-Q · filed 2025-08-11 | |||||
| 2024-03-31 | 4.04% 10-Q · filed 2025-05-08 | |||||
| 2023-12-31 | 3.83% 10-K · filed 2025-02-27 | |||||
| 2023-09-30 | 3.80% 10-Q · filed 2024-11-12 | |||||
| 2023-06-30 | 3.80% 10-Q · filed 2024-08-12 | |||||
| 2023-03-31 | 3.80% 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | 2.02% 10-K · filed 2024-03-21 | |||||
| 2022-09-30 | 2.00% 10-Q · filed 2023-11-09 | 2.02% 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | 1.90% 10-Q · filed 2023-08-03 | 1.93% 10-Q · filed 2022-08-01 | ||||
| 2022-03-31 | 1.85% 10-Q · filed 2023-05-04 | |||||
| 2021-12-31 | 0.85% 10-K · filed 2023-03-15 | |||||
| 2021-09-30 | 0.76% 10-Q · filed 2022-11-09 | |||||
| 2021-06-30 | 0.76% 10-Q · filed 2022-08-01 | |||||
| 2020-06-30 | 0.36% 10-Q · filed 2020-08-13 | |||||
| 2019-06-30 | 2.43% 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |